<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="article-commentary" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29708509</article-id>
<article-id pub-id-type="pmc">5983308</article-id>
<article-id pub-id-type="publisher-id">121052</article-id>
<article-id pub-id-type="doi">10.1172/JCI121052</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Commentary</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>DEPDC5 takes a second hit in familial focal epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Anderson</surname>
<given-names>Matthew P.</given-names>
</name>
</contrib>
</contrib-group>
<aff>Departments of Neurology and Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Boston Children’s Hospital Intellectual and Developmental Disabilities Research Center, Boston, Massachusetts, USA. Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Matthew P. Anderson, Center for Life Science, 330 Brookline Ave, E/CLS-645, Boston, Massachusetts 02215, USA. Phone: 617.735.3202; Email: <email>Matthew_Anderson@bidmc.harvard.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The author has declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2018-04-30T16:00:00-0400" publication-format="electronic">
<day>30</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2018-06-01T16:00:00-0400" publication-format="print">
<day>1</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>6</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>128</volume>
<issue>6</issue>
<fpage>2194</fpage>
<lpage>2196</lpage>
<permissions>
<copyright-statement>Copyright © 2018, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/121052">This article is available online at https://www.jci.org/articles/view/121052</self-uri>
<abstract>
<p>Loss-of-function mutations in a single allele of the gene encoding DEP domain–containing 5 protein (DEPDC5) are commonly linked to familial focal epilepsy with variable foci; however, a subset of patients presents with focal cortical dysplasia that is proposed to result from a second-hit somatic mutation. In this issue of the <italic>JCI</italic>, Ribierre and colleagues provide several lines of evidence to support second-hit <italic>DEPDC5</italic> mutations in this disorder. Moreover, the authors use in vivo, in utero electroporation combined with CRISPR-Cas9 technology to generate a murine model of the disease that recapitulates human manifestations, including cortical dysplasia–like changes, focal seizures, and sudden unexpected death. This study provides important insights into familial focal epilepsy and provides a preclinical model for evaluating potential therapies.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>